Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Wednesday. The firm set a "hold" rating on the stock.
LadRx Stock Performance
LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The firm's 50 day moving average price is $0.10.
Get LadRx alerts:LadRx Company Profile
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
Featured Articles
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
